Trastuzumab/pertuzumab combination therapy stimulates antitumor responses through complement-dependent cytotoxicity and phagocytosis-Reference-Cited by-同舟云学术

Trastuzumab/pertuzumab combination therapy stimulates antitumor responses through complement-dependent cytotoxicity and phagocytosis

Published:2022-03-22 Issue:6 Volume:7 Page:
ISSN:2379-3708
Container-title:JCI Insight
language:en
Short-container-title:

Author:

Tsao Li-Chung^ORCID,Crosby Erika J.^ORCID,Trotter Timothy N.,Wei Junping,Wang Tao,Yang Xiao,Summers Amanda N.,Lei Gangjun,Rabiola Christopher A.,Chodosh Lewis A.^ORCID,Muller William J.,Lyerly Herbert Kim^ORCID,Hartman Zachary C.^ORCID

Funder

National Institutes of Health

U.S. Department of Defense

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://insight.jci.org/articles/view/155636/files/pdf

Reference75 articles.

1. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

2. erb B-2 Is a Potent Oncogene When Overexpressed in NIH/3T3 Cells

3. Trastuzumab — Mechanism of Action and Use in Clinical Practice

4. Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group

5. Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in HER2-Targeted Therapies: From monoclonal antibodies to dual inhibitors developments in cancer treatment;Bioorganic Chemistry;2024-10

2. Trastuzumab, a monoclonal anti-HER2 antibody modulates cytotoxicity against cholangiocarcinoma via multiple mechanisms;International Immunopharmacology;2024-09

3. Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer;Cancers;2024-07-24

4. Fc–Fc interactions and immune inhibitory effects of IgG4: implications for anti-PD-1 immunotherapies;Journal for ImmunoTherapy of Cancer;2024-06

5. Broad Epitope Coverage of Therapeutic Multi-Antibody Combinations Targeting SARS-CoV-2 Boosts In Vivo Protection and Neutralization Potency to Corner an Immune-Evading Virus;Biomedicines;2024-03-13